Jeffrey Terrell, M.D.

I am an Otolaryngologist who has been treatment patients with HHT for more than 20 years. More recently, I have become much more involved with HHT.org, and I'm seeing more patients with HHT and ENT issues, particularly nosebleeds. My interest in treatment patients with HHT at the University of Michigan has grown because of the following: first, I believe HHT patients are complex. They have the potential to have significant issues related to their AVMs. I find that most community doctors and specialists and hospitals don't have the expertise to manage them, sometimes they don't have the expertise to diagnose them. If ever there was a "tertiary care" type of disorder, HHT is one of them. I am also happy to report that a few new therapies for HHT and nosebleeds have been developed recently, including AVASTIN injections, AVASTIN spray, and now injection sclerotherapy. My patients with each of these therapies have had improvements that I have not seen in the past, so I feel that now we have some excellent options. Finally, I have learned now to manage those few patients that need to go to the OR to treat large nasal malformations. There is a learning curve to managing severe nosebleeds, and I feel we have the opportunity to identify and treat those patients with more severe disease. I am opening new appointment types for HHT patients next month. I will work to get patients into other specialists at the U of Michigan, who have expertise and interest in HHT. We have excellent interventional radiologists, to tackle pulmonary AVMs. I usually set patients up for screening tests, when I see them.